Evidence map›Paper›PMID 39876588›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2025

Brain Age as a New Measure of Disease Stratification in Huntington's Disease.

Pubu M Abeyasinghe, James H Cole, Adeel Razi, Govinda R Poudel, Jane S Paulsen, Sarah J Tabrizi, Jeffrey D Long, Nellie Georgiou-Karistianis

Abstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Association of imaging-defined brain age with disease severity and adverse outcomes in CADASIL.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Collaborative AI for precision neurorehabilitation: a roadmap.Journal of neuroengineering and rehabilitation · 2025
    Review
  4. Regional brain aging patterns reveal disease-specific pathways of neurodegeneration.medRxiv : the preprint server for health sciences · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pubu M AbeyasingheSchool of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.
James H ColeCentre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom.
Adeel RaziSchool of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.
Govinda R PoudelMary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
Jane S PaulsenDepartment of Neurology, University of Wisconsin, Madison, Wisconsin, USA.
Sarah J TabriziUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID https://orcid.org/0000-0001-6470-7169
Jeffrey D LongDepartment of Psychiatry, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
Nellie Georgiou-KaristianisSchool of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-0718-6760

Funding

NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON'S DISEASER01NS040068 · NINDS · UNIVERSITY OF IOWA · PI PAULSEN, JANE S · 2001 to 2013
$48.5M
Preparing for preventive clinical trials in Huntington's diseaseU01NS105509 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI PAULSEN, JANE S · 2020 to 2025
$2.5M
Integrated approach to protein biomarker identification in Huntington DiseaseU01NS082089 · NINDS · UNIVERSITY OF IOWA · PI CHELSKY, DANIEL, PAULSEN, JANE S · 2013 to 2015
$1.7M
Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington diseaseU01NS103475 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI PAULSEN, JANE S · 2020 to 2022
$1.7M
Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington diseaseR01NS103475 · NINDS · UNIVERSITY OF IOWA · PI PAULSEN, JANE S, ZHANG, YING · 2017 to 2018
$1.2M
Preparing for preventive clinical trials in Huntington's diseaseR01NS105509 · NINDS · UNIVERSITY OF IOWA · PI PAULSEN, JANE S · 2018 to 2018
$658k
Monash UniversityNINDS NIH HHS R01 NS040068NINDS NIH HHS R01 NS103475NINDS NIH HHS R01 NS105509NINDS NIH HHS U01 NS082089NINDS NIH HHS U01 NS103475NINDS NIH HHS U01 NS105509
6 · The paper itself

Abstract

backgroundDespite advancements in understanding Huntington's disease (HD) over the past two decades, absence of disease-modifying treatments remains a challenge. Accurately characterizing progression states is crucial for developing effective therapeutic interventions. Various factors contribute to this challenge, including the need for precise methods that can account for the complex nature of HD progression.

objectiveThis study aims to address this gap by leveraging the concept of the brain's biological age as a foundation for a data-driven clustering method to delineate various states of progression. Brain-predicted age, influenced by somatic expansion and its impact on brain volumes, offers a promising avenue for stratification by stratifying subgroups and determining the optimal timing for interventions.

methodsTo achieve this, data from 953 participants across diverse cohorts, including PREDICT-HD, TRACK-HD, and IMAGE-HD, were meticulously analyzed. Brain-predicted age was computed using sophisticated algorithms, and participants were categorized into four groups based on CAG and age product score. Unsupervised k-means clustering with brain-predicted age difference (brain-PAD) was then employed to identify distinct progression states.

resultsThe analysis revealed significant disparities in brain-predicted age between HD participants and controls, with these differences becoming more pronounced as the disease progressed. Brain-PAD demonstrated a correlation with disease severity, effectively identifying five distinct progression states characterized by significant longitudinal disparities.

conclusionsThese findings highlight the potential of brain-PAD in capturing HD progression states, thereby enhancing prognostic methodologies and providing valuable insights for future clinical trial designs and interventions. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

AgingBrainHuntington DiseaseAdultAgedDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle Agedbrain ageHuntington's diseasestates of progression

Identifiers

PMID39876588
PMCPMC12006897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.